SYMPHOGEN Secures EUR 33 million Financing to Support Clinical Development of Antibody Products - Gilde Healthcare

SYMPHOGEN Secures EUR 33 million Financing to Support Clinical Development of Antibody Products

3 februari 2009

COPENHAGEN, Denmark – Symphogen A/S today announced the closing of a € 33 million (approximately U.S. $44 million) financing. Existing investors participated in the round, which was led by Essex Woodlands Health Ventures. The financing will be used to mature the company’s product pipeline of antibody therapeutics, particularly within the field of oncology.

“This significant financial commitment from our current investors demonstrates their confidence in Symphogen’s innovative pipeline and antibody discovery and manufacturing technologies,”

said Kirsten Drejer, CEO of Symphogen.

“The current funding will support the advancement of our lead oncology program, Sym004, towards early clinical studies as Symphogen continues to build a competitive oncology franchise. Coinciding with our strategic decision to focus our internal R&D resources on further maturing our oncology pipeline, Symphogen also plans to broaden our external collaborative activities by engaging in partnership discussions for our anti-RSV and anti-RhD recombinant polyclonal antibody programs.”

Martin Edwards, Chairman of the Board of Directors, commented that

“Symphogen’s cutting-edge technology platforms and pipeline of oncology antibody therapeutics represent a promising approach to treating cancer. I believe that the company has made significant progress in advancing several of its antibody programs. Symphogen’s strong investor syndicate remains committed to supporting the company’s continued pipeline development and business strategy.”

About Sym004

Sym004 is a recombinant IgG1 antibody product consisting of two antibodies against the epidermal growth factor receptor (EGFR). Similar to marketed monoclonal antibodies, Sym004 inhibits cancer cells in vitro by inhibition of ligand binding, receptor activation and downstream signaling.

In addition, Sym004 induces rapid and efficient internalization and degradation of the EGF receptor due to the simultaneous binding of full length Sym004 antibodies to non-overlapping epitopes. This removal of the EGF receptor leads to a superior anti-tumor response of Sym004 as compared to marketed monoclonal EGFR antibodies in vitro and in vivo. Preliminary safety data indicate that Sym004 has a safety profile similar to marketed monoclonal antibodies and a full set of regulatory toxicology studies have been initiated.

About Symphogen

Symphogen is the leader in developing recombinant polyclonal antibodies (pAb), a new class of biopharmaceuticals for the treatment of serious human diseases. By employing its pioneering antibody discovery and manufacturing technologies, Symphogen generates recombinant antibody compositions that capture the diversity and effectiveness of the natural immune system. Symphogen is building a proprietary product pipeline within several disease areas, including infectious diseases and cancer.  Symphogen is a private biopharmaceutical company with more than 70 employees, based in Copenhagen, Denmark. Refer to www.symphogen.com  for further information on Symphogen.

Meer nieuws

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17 oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15 oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14 oktober 2025